Related Experiment Video
Updated: Jun 18, 2026
08:17
A Mouse Model of Orthopedic Surgery to Study Postoperative Cognitive Dysfunction and Tissue Regeneration
Published on: February 27, 2018
Inflammation: a bridge between postoperative cognitive dysfunction and Alzheimer's disease
Zhonghua Hu1, Yangwen Ou, Kaiming Duan
1Department of Anesthesiology, The Third Xiangya Hospital of Xiangya Medical School, Centralsouth University, 138 Tongzipo Road, Changsha 410013, Hunan, China. loghhh213@163.com
Medical Hypotheses
|December 1, 2009
Summary
Postoperative cognitive dysfunction (POCD) and Alzheimer's disease (AD) may share a common cause: inflammation. Targeting neuroinflammatory responses could be key to preventing and treating both conditions.
Area of Science:
- Neuroscience
- Immunology
- Gerontology
Background:
- Postoperative cognitive dysfunction (POCD) is a decline in cognitive function after surgery, with unknown exact pathophysiological mechanisms.
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder in the elderly, lacking satisfactory prevention and therapy due to unknown etiology.
- Neuroinflammation is implicated in both POCD and AD pathogenesis.
Purpose of the Study:
- To investigate the potential common role of inflammatory and neuroinflammatory responses in the pathogenesis of POCD and AD.
- To hypothesize that inflammatory response is an initial factor in the development of POCD and AD.
- To suggest that targeting neuroinflammation is a potential therapeutic strategy for both conditions.
Main Methods:
- Review of animal and human studies linking POCD to peripheral and neuroinflammatory responses.
- Examination of the role of neuroinflammation in AD pathophysiology.
- Hypothesis formulation based on shared inflammatory pathways.
Main Results:
- POCD incidence is not clearly influenced by anesthesia type or depth, suggesting other factors like inflammation are crucial.
- Microglial activation is identified as a potential common pathogenic mechanism in POCD and AD.
- Evidence suggests a strong association between neuroinflammatory responses and both POCD and AD.
Conclusions:
- Inflammatory response, particularly neuroinflammation, is hypothesized as a key factor in the development of POCD and AD.
- Effective prevention and therapy for POCD and AD should consider anti-inflammatory strategies, especially targeting neuroinflammation.
- Further research into the specific mechanisms of neuroinflammation in POCD and AD is warranted.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:19Psychoneuroimmunology: Diabetes and Cancer
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...